FDA Approves Radius Health’s TYMLOS™ (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Go back to FDA Approves Radius Health’s TYMLOS™ (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture| (NASDAQ: RDUS) | Delayed: 30.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.00 | 52 Week High | $75.47 | |||
| Open | $30.00 | 52 Week Low | $24.75 | |||
| Day High | $30.00 | P/E | N/A | |||
| Day Low | $30.00 | EPS | $0.00 | |||
| Volume | 829,016 | |||||
